WO2009020028A1 - Determination and suppression of expression level of g protein-coupled receptor kinase 4 gene in breast cancer cell - Google Patents

Determination and suppression of expression level of g protein-coupled receptor kinase 4 gene in breast cancer cell Download PDF

Info

Publication number
WO2009020028A1
WO2009020028A1 PCT/JP2008/063701 JP2008063701W WO2009020028A1 WO 2009020028 A1 WO2009020028 A1 WO 2009020028A1 JP 2008063701 W JP2008063701 W JP 2008063701W WO 2009020028 A1 WO2009020028 A1 WO 2009020028A1
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
cancer cell
gene
expression level
suppression
Prior art date
Application number
PCT/JP2008/063701
Other languages
French (fr)
Japanese (ja)
Inventor
Masahiko Kuroda
Masakatsu Takanashi
Jun Matsubayashi
Kosuke Oikawa
Masami Tanaka
Original Assignee
Konica Minolta Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konica Minolta Holdings, Inc. filed Critical Konica Minolta Holdings, Inc.
Priority to JP2009526409A priority Critical patent/JP4981134B2/en
Publication of WO2009020028A1 publication Critical patent/WO2009020028A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

It was first discovered that GRK4 is highly expressed in a human breast cancer cell, and it is intended to provide a primer set having specific sequences capable of determining the expression level of a GRK4 gene by PCR, and GRK4 siRNA capable of suppressing human breast cancer cell proliferation. As means for resolution, the sequences of the primer set specific for the GRK4 gene for PCR are represented by SEQ ID NOS: 1 and 2, and the sequences of a double-stranded RNA for siRNA are represented by SEQ ID NOS: 3 to 8.
PCT/JP2008/063701 2007-08-03 2008-07-30 Determination and suppression of expression level of g protein-coupled receptor kinase 4 gene in breast cancer cell WO2009020028A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009526409A JP4981134B2 (en) 2007-08-03 2008-07-30 Quantification and suppression of G protein-coupled receptor kinase 4 gene expression in breast cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007203189 2007-08-03
JP2007-203189 2007-08-03

Publications (1)

Publication Number Publication Date
WO2009020028A1 true WO2009020028A1 (en) 2009-02-12

Family

ID=40341262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063701 WO2009020028A1 (en) 2007-08-03 2008-07-30 Determination and suppression of expression level of g protein-coupled receptor kinase 4 gene in breast cancer cell

Country Status (2)

Country Link
JP (1) JP4981134B2 (en)
WO (1) WO2009020028A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037996A2 (en) * 2002-10-24 2004-05-06 Duke University Evaluation of breast cancer states and outcomes using gene expression profiles
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037996A2 (en) * 2002-10-24 2004-05-06 Duke University Evaluation of breast cancer states and outcomes using gene expression profiles
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MATSUBAYASHI J. ET AL.: "DNA Micro Array ni yoru Nyugan no Idenshi Hatsugen Kaiseki", NIHON GAN GAKKAI GAKUJUTSU SOKAI KIJI, vol. 64, 2005, pages 285 + ABSTR. NO. PA2-0624 *
MATSUBAYASHI J. ET AL.: "Nyugan ni Okeru G-protein-coupled receptor kinase 4 no Hatsugen Kaiseki", JOURNAL OF TOKYO MEDICAL COLLEGE, vol. 64, no. 4, 2007, pages 467 - 468 *
PREMONT R.T. ET AL.: "Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants", J. BIOL. CHEM., vol. 271, 1996, pages 6403 - 6410, XP001008847 *
SANADA H. ET AL.: "Amelioration of genetic hypertension by suppression of renal G protein-coupled receptor kinase type 4 expression", HYPERTENSION, vol. 47, 2006, pages 1131 - 1139 *

Also Published As

Publication number Publication date
JPWO2009020028A1 (en) 2010-11-04
JP4981134B2 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
EP2426206A3 (en) Selecting and stablizing dsRNA constructs
ZA200908342B (en) Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2008118212A3 (en) In vivo delivery of double stranded rna to a target cell
WO2007136736A3 (en) Methods for nucleic acid sorting and synthesis
MX2009008508A (en) Compositions and methods to prevent cancer with cupredoxins.
AU2003294447A8 (en) Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2010105815A3 (en) Improved detection of gene expression
WO2011068909A3 (en) Aptamer cell compositions
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
IL202090A0 (en) METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
WO2010028054A8 (en) Compositions and methods for inhibiting expression of mutant egfr gene
WO2007085497A3 (en) Markers for the prediction of outcome of anthracycline treatment
Sun et al. MicroRNA-4465 suppresses tumor proliferation and metastasis in non-small cell lung cancer by directly targeting the oncogene EZH2
IN2012DN01979A (en)
EP2315857A4 (en) Methods and compositions for continuous single-molecule nucleic acid sequencing by synthesis with fluorogenic nucleotides
WO2007100684A3 (en) Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
WO2013040393A3 (en) Genes contributing to survival of cancer cells
WO2011006145A3 (en) Compositions and methods for mammalian genetics and uses thereof
WO2010051204A3 (en) Bcr-abl variants
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
WO2009020028A1 (en) Determination and suppression of expression level of g protein-coupled receptor kinase 4 gene in breast cancer cell
WO2009104896A3 (en) Nucleic-acid pharmaceutical composition for cancer therapy
WO2011065677A3 (en) Pharmaceutical composition for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791932

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009526409

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791932

Country of ref document: EP

Kind code of ref document: A1